Letters
Dabigatran thrombotic events
Thrombotic events after discontinuing dabigatran: rebound or resumption?
BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e4469 (Published 03 July 2012) Cite this as: BMJ 2012;345:e4469
- Katie M Thorne, medical registrar1,
- Stephen Dee, medical consultant2,
- Sisira Jayathissa, medical consultant2
- 1Palliative Care Centre, Wellington Hospital, Wellington, New Zealand
- 2Medical Department, Hutt Hospital, Wellington, New Zealand
- Katie.Thorne{at}hyms.ac.uk
The REMODEL trial has suggested that stopping dabigatran does not produce a rebound thrombotic effect.1 2 However, others have raised the possibility of this.3
Such rebound pro-thrombotic activity and clusters of thrombotic events have been reported with heparin and older anti-thrombotic drugs, and concerns are now being expressed about the newer anticoagulants, including the factor Xa inhibitor, rivaroxaban, and oral direct thrombin …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £138 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.